Go to deals
Private Equity | Healthcare

The Providence Projects has been acquired by UKAT Group

Celebrity-success rehabilitation center, The Providence Projects, has joined The UK Addiction Treatment (UKAT) Group, backed by Sullivan Street Equity Partners.

Established in 1996, The Providence Projects is one of the UK’s leading providers of affordable private alcohol and drug rehabilitation services. With nearly three decades of experience, Providence has built a strong reputation for delivering high-quality, accessible care to individuals and families affected by addiction. Based in Bournemouth, the group offers a comprehensive range of evidence-based treatments for substance misuse, including alcohol, cocaine, heroin, prescription drugs and behavioral addictions such as gambling. The Providence team is made up of highly experienced addiction specialists, therapists and support staff, all committed to helping clients achieve lasting recovery.

Treatment at Providence is centered around compassion, respect and clinical excellence. Programs are personalized and combine one-to-one therapy, group counseling, cognitive behavioral therapy (CBT), 12-step facilitation and holistic treatments, all tailored to the specific needs of each individual. Detox services are medically supervised, with aftercare planning forming a core component of their relapse prevention approach. The Providence Projects also offers a range of supported accommodation options and provides extensive family support services to ensure a well-rounded recovery journey. Over the years, Providence has helped thousands of clients transform their lives and continues to be recognized for its commitment to affordability, professionalism and long-term outcomes.

UKAT Group is a nationwide network of Care Quality Commission (CQC)-regulated rehabilitation clinics, dedicated to providing high-quality, evidence-based addiction treatment. Their mission is to help individuals achieve long-term recovery through professional medical detox, rehabilitation therapy and ongoing support. UKAT offers treatment for a wide range of substance and behavioral addictions, including alcohol and drug addiction, gambling addiction, eating disorders and dual diagnosis involving co-occurring mental health conditions.

Oaklins S&W, based in the UK, acted as the lead advisor to the shareholders on the sale of the business to UKAT. Its strong sector credentials enabled it to win a competitive pitch process. The team subsequently advised on all aspects of the transaction, from initial buyer research and sale preparation to drafting marketing materials, leading negotiations and buyer meetings, managing due diligence and overseeing general project management throughout the deal.

Parties

Talk to the deal team

Ben Laing

Partner
London, United Kingdom
Oaklins S&W

Stuart Goodman

Partner
London, United Kingdom
Oaklins S&W

Oliver Aspinall

Senior Manager
London, United Kingdom
Oaklins S&W

Related deals

UKAT Group has acquired Bayberry Limited
Private Equity | Healthcare

UKAT Group has acquired Bayberry Limited

UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.

Learn more
Medicija has acquired Saulės Šeimos Medicinos Centras
Healthcare

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Learn more
Quimpharma has completed the divestiture of a product portfolio to Megalabs
Healthcare

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Learn more